カテゴリー： QYResearch, 世界, 医療/バイオ

ウイルス性喘息治療のグローバル市場2023年：経口、注射

◆英語タイトル：Global Virus-Induced Asthma Treatment Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA7573）◆商品コード：QYR23MA7573
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：92
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界のウイルス性喘息治療市場について調査・分析し、世界のウイルス性喘息治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（経口、注射）、用途別セグメント分析（病院、クリニック、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、AstraZeneca plc、Sanofi SA、Novartis AG、Mylan NV、Regeneron、F.Hoffman-La Roche Ltd.、Teva Pharmaceuticals Industries Ltd.、Merck & Co.、Cipla Limited、GlaxoSmithKline plc.などが含まれています。世界のウイルス性喘息治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ウイルス性喘息治療市場規模を推定する際に考慮しました。

・ウイルス性喘息治療市場の概要
- ウイルス性喘息治療のタイプ別セグメント
- 世界のウイルス性喘息治療市場規模：タイプ別分析（経口、注射）
- ウイルス性喘息治療の用途別セグメント
- 世界のウイルス性喘息治療市場規模：用途別分析（病院、クリニック、その他）
- 世界のウイルス性喘息治療市場規模予測（2018年-2029年）

・ウイルス性喘息治療市場の成長トレンド
- ウイルス性喘息治療の地域別市場規模（2018年-2029年）
- ウイルス性喘息治療市場ダイナミクス
- ウイルス性喘息治療の業界動向
- ウイルス性喘息治療市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・タイプ別セグメント：経口、注射
- 世界のウイルス性喘息治療のタイプ別市場規模（2018年-2023年）
- 世界のウイルス性喘息治療のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、クリニック、その他
- 世界のウイルス性喘息治療の用途別市場規模（2018年-2023年）
- 世界のウイルス性喘息治療の用途別市場規模（2024年-2029年）

・ウイルス性喘息治療の地域別市場規模
- 北米のウイルス性喘息治療市場規模（2018年-2029年）
- アメリカのウイルス性喘息治療市場規模（2018年-2029年）
- ヨーロッパのウイルス性喘息治療市場規模（2018年-2029年）
- アジア太平洋のウイルス性喘息治療市場規模（2018年-2029年）
- 中国のウイルス性喘息治療市場規模（2018年-2029年）
- 日本のウイルス性喘息治療市場規模（2018年-2029年）
- 韓国のウイルス性喘息治療市場規模（2018年-2029年）
- インドのウイルス性喘息治療市場規模（2018年-2029年）
- オーストラリアのウイルス性喘息治療市場規模（2018年-2029年）
- 中南米のウイルス性喘息治療市場規模（2018年-2029年）
- 中東・アフリカのウイルス性喘息治療市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
AstraZeneca plc、Sanofi SA、Novartis AG、Mylan NV、Regeneron、F.Hoffman-La Roche Ltd.、Teva Pharmaceuticals Industries Ltd.、Merck & Co.、Cipla Limited、GlaxoSmithKline plc.

・アナリストの観点/結論

・調査方法とデータソース

Highlights
The global Virus-Induced Asthma Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Virus-Induced Asthma Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Virus-Induced Asthma Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Virus-Induced Asthma Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Virus-Induced Asthma Treatment include AstraZeneca plc, Sanofi SA, Novartis AG, Mylan NV, Regeneron, F.Hoffman-La Roche Ltd., Teva Pharmaceuticals Industries Ltd., Merck & Co. and Cipla Limited, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Virus-Induced Asthma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus-Induced Asthma Treatment.
The Virus-Induced Asthma Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Virus-Induced Asthma Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Virus-Induced Asthma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AstraZeneca plc
Sanofi SA
Novartis AG
Mylan NV
Regeneron
F.Hoffman-La Roche Ltd.
Teva Pharmaceuticals Industries Ltd.
Merck & Co.
Cipla Limited
GlaxoSmithKline plc.
Segment by Type
Oral
Injection
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Virus-Induced Asthma Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Virus-Induced Asthma Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Virus-Induced Asthma Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Virus-Induced Asthma Treatment Market Perspective (2018-2029)
2.2 Virus-Induced Asthma Treatment Growth Trends by Region
2.2.1 Global Virus-Induced Asthma Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Virus-Induced Asthma Treatment Historic Market Size by Region (2018-2023)
2.2.3 Virus-Induced Asthma Treatment Forecasted Market Size by Region (2024-2029)
2.3 Virus-Induced Asthma Treatment Market Dynamics
2.3.1 Virus-Induced Asthma Treatment Industry Trends
2.3.2 Virus-Induced Asthma Treatment Market Drivers
2.3.3 Virus-Induced Asthma Treatment Market Challenges
2.3.4 Virus-Induced Asthma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Virus-Induced Asthma Treatment Players by Revenue
3.1.1 Global Top Virus-Induced Asthma Treatment Players by Revenue (2018-2023)
3.1.2 Global Virus-Induced Asthma Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Virus-Induced Asthma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Virus-Induced Asthma Treatment Revenue
3.4 Global Virus-Induced Asthma Treatment Market Concentration Ratio
3.4.1 Global Virus-Induced Asthma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Virus-Induced Asthma Treatment Revenue in 2022
3.5 Virus-Induced Asthma Treatment Key Players Head office and Area Served
3.6 Key Players Virus-Induced Asthma Treatment Product Solution and Service
3.7 Date of Enter into Virus-Induced Asthma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Virus-Induced Asthma Treatment Breakdown Data by Type
4.1 Global Virus-Induced Asthma Treatment Historic Market Size by Type (2018-2023)
4.2 Global Virus-Induced Asthma Treatment Forecasted Market Size by Type (2024-2029)
5 Virus-Induced Asthma Treatment Breakdown Data by Application
5.1 Global Virus-Induced Asthma Treatment Historic Market Size by Application (2018-2023)
5.2 Global Virus-Induced Asthma Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Virus-Induced Asthma Treatment Market Size (2018-2029)
6.2 North America Virus-Induced Asthma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Virus-Induced Asthma Treatment Market Size by Country (2018-2023)
6.4 North America Virus-Induced Asthma Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Virus-Induced Asthma Treatment Market Size (2018-2029)
7.2 Europe Virus-Induced Asthma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Virus-Induced Asthma Treatment Market Size by Country (2018-2023)
7.4 Europe Virus-Induced Asthma Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Virus-Induced Asthma Treatment Market Size (2018-2029)
8.2 Asia-Pacific Virus-Induced Asthma Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Virus-Induced Asthma Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Virus-Induced Asthma Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Virus-Induced Asthma Treatment Market Size (2018-2029)
9.2 Latin America Virus-Induced Asthma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Virus-Induced Asthma Treatment Market Size by Country (2018-2023)
9.4 Latin America Virus-Induced Asthma Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Virus-Induced Asthma Treatment Market Size (2018-2029)
10.2 Middle East & Africa Virus-Induced Asthma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Virus-Induced Asthma Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Virus-Induced Asthma Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca plc
11.1.1 AstraZeneca plc Company Detail
11.1.2 AstraZeneca plc Business Overview
11.1.3 AstraZeneca plc Virus-Induced Asthma Treatment Introduction
11.1.4 AstraZeneca plc Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.1.5 AstraZeneca plc Recent Development
11.2 Sanofi SA
11.2.1 Sanofi SA Company Detail
11.2.2 Sanofi SA Business Overview
11.2.3 Sanofi SA Virus-Induced Asthma Treatment Introduction
11.2.4 Sanofi SA Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.2.5 Sanofi SA Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Virus-Induced Asthma Treatment Introduction
11.3.4 Novartis AG Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.3.5 Novartis AG Recent Development
11.4 Mylan NV
11.4.1 Mylan NV Company Detail
11.4.2 Mylan NV Business Overview
11.4.3 Mylan NV Virus-Induced Asthma Treatment Introduction
11.4.4 Mylan NV Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.4.5 Mylan NV Recent Development
11.5 Regeneron
11.5.1 Regeneron Company Detail
11.5.2 Regeneron Business Overview
11.5.3 Regeneron Virus-Induced Asthma Treatment Introduction
11.5.4 Regeneron Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.5.5 Regeneron Recent Development
11.6 F.Hoffman-La Roche Ltd.
11.6.1 F.Hoffman-La Roche Ltd. Company Detail
11.6.2 F.Hoffman-La Roche Ltd. Business Overview
11.6.3 F.Hoffman-La Roche Ltd. Virus-Induced Asthma Treatment Introduction
11.6.4 F.Hoffman-La Roche Ltd. Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.6.5 F.Hoffman-La Roche Ltd. Recent Development
11.7 Teva Pharmaceuticals Industries Ltd.
11.7.1 Teva Pharmaceuticals Industries Ltd. Company Detail
11.7.2 Teva Pharmaceuticals Industries Ltd. Business Overview
11.7.3 Teva Pharmaceuticals Industries Ltd. Virus-Induced Asthma Treatment Introduction
11.7.4 Teva Pharmaceuticals Industries Ltd. Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.7.5 Teva Pharmaceuticals Industries Ltd. Recent Development
11.8 Merck & Co.
11.8.1 Merck & Co. Company Detail
11.8.2 Merck & Co. Business Overview
11.8.3 Merck & Co. Virus-Induced Asthma Treatment Introduction
11.8.4 Merck & Co. Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.8.5 Merck & Co. Recent Development
11.9 Cipla Limited
11.9.1 Cipla Limited Company Detail
11.9.2 Cipla Limited Business Overview
11.9.3 Cipla Limited Virus-Induced Asthma Treatment Introduction
11.9.4 Cipla Limited Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.9.5 Cipla Limited Recent Development
11.10 GlaxoSmithKline plc.
11.10.1 GlaxoSmithKline plc. Company Detail
11.10.2 GlaxoSmithKline plc. Business Overview
11.10.3 GlaxoSmithKline plc. Virus-Induced Asthma Treatment Introduction
11.10.4 GlaxoSmithKline plc. Revenue in Virus-Induced Asthma Treatment Business (2018-2023)
11.10.5 GlaxoSmithKline plc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ ウイルス性喘息治療のグローバル市場2023年：経口、注射(Global Virus-Induced Asthma Treatment Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 腫瘍溶解性ウイルス薬物治療のグローバル市場2023年：フェーズ1、フェーズ2、その他
  • ヘパリン誘発性血小板減少症治療のグローバル市場2023年：活性化因子 X 阻害剤 ヘパリン誘発性血小板減少症治療、直接トロンビン阻害剤 ヘパリン誘発性血小板減少症治療、ヘパリノイド ヘパリン誘発性血小板減少症治療、フォンダパリヌクス ヘパリン誘発性血小板減少症治療、ヘパリン＆ビタミン K アンタゴニスト療法 ヘパリン誘発性血小板減少症治療
  • 喘息治療器具の世界市場見通し2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆